pneumococcal vaccination series for children and adolescents at increased risk for pneumococcal disease. According to a 2025 study of 2015-2019 CDC ABC surveillance data, including three groups, one of which consisted of children
According to U.S. customs data, peptide imports from China nearly doubled to $328 million in the first three quarters of 2025, fueling a surge of unregulated operators selling research-only chemicals with no quality control or accountability....
through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2025, the Group employed around 88,000 people and had sales of 45.6 billion euros. R&D expenses amounted to 5.8 billion euros....
commercial growth for EVERY: in the first four months of 2026, the company secured annual orders worth 550% of its total 2025 order volume. This surge is driven by strong adoption across B2B retail channels, including national placement in Target...
the treatment of adult patients with relapsed or refractory DLBCL who are not eligible for ASCT. In addition, in December 2025, the EMA approved Minjuvi, in combination with lenalidomide and rituximab, for the treatment of adult patients with...
View Research, the global collagen market is expected to reach $26.2 billion by 2033, growing at a CAGR of 11.0% from 2025 to 2033. While collagen supplementation has become one of the fastest-growing segments within wellness and beauty, consumer...
across diabetes management, healthcare solutions, life sciences and diagnostics. PHC Group’s consolidated net sales in FY2025 were JPY 364 billion with global distribution of products and services in more than 125 countries and regions. For more...
an infected individual may develop COVID-19.6 The U.S. Centers for Disease and Control estimates that between October 1, 2025 and May 23, 2026 there were 3.8-12.4 million new cases in the U.S., resulting in 800,000 – 2.3 million outpatient visits,...
a Shanghai-based clinical-stage cell therapy company, announced their strategic partnership which began in December 2025. The milestone: the first patient has been dosed in an investigator initiated trial (IIT) using ImmuXell’s TCR-T cell therapy...
fourth among men,4 and it is estimated that there will be approximately 84,870 new cases of bladder cancer in the U.S. in 2025.4 Historically, 75% of bladder cancer presents as NMIBC.5 In patients with high-risk NMIBC, intravesical BCG remains the...
This latest milestone builds upon the company's landmark first-in-human procedures reported in September and December of 2025. In up to nine-months follow-up of the initial four cases, the RoseDoc platform demonstrates exceptional efficacy, safety...
system. With more than 9 000 people in approximately 40 countries, the company generated revenue of €7.7 billion in 2025..
sciences. This recognition follows a defining period of momentum for Sprout and its flagship treatment, Addyi. In December 2025, the U.S. Food and Drug Administration approved an expanded indication for Addyi to include all women under 65 with...
United States. Its products are available in over 90 countries, and its R&D activities focus on 10 therapeutic areas. In 2025, IBSA celebrated the 40th anniversary of its acquisition by current President and CEO, Arturo Licenziati, who has...
said Pieter Muntendam MD, founder, President and CEO of SQ Innovation. "Following FDA approval in the United States in 2025, these European regulatory milestones reflect our commitment to bringing this transformative at-home therapy to patients...
for autoimmune diseases and inflammatory disorders. Cellenkos was granted US patent (US12472182B2) on November 18, 2025, for their technology covering "Compositions comprising regulatory t cells and methods of" producing and using them. Using its...
participants in the third quarter of 2026." Dr. Wu added, "Based on the positive clinical results announced in December 2025 from our 13-week U.S. Phase II study of ASC30 in participants with obesity or overweight, the Company expects to obtain the...
up with Cost Plus Drugs provides another option for cash-paying patients to access Eliquis directly. This follows the 2025 launch of a direct-to-patient offering through the BMS-Pfizer Alliance’s patient resource Eliquis 360 Support, which is also...
program will be featured at leading transplant and virology meetings in 2026, building on findings presented at the ASN in 2025. Alongside its core focus on polyomaviruses, Orthogon is advancing programs in additional areas of unmet need in...
Sabbagh as General Manager, France. Following a €32 million Series A investment by MVM Partners announced in November 2025, Avanzanite is scaling its European infrastructure into a single, integrated platform across 32 countries – designed to bring...
